REG - Avacta Group PLC - Avacta to Present at ESMO Congress

AvactaAnnouncement

30/07/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250730:nRSd1598Ta&default-theme=true

RNS Number : 1598T  Avacta Group PLC  30 July 2025

Avacta to Present New FAP Dox (AVA6000) Data at the European Society for
Medical Oncology (ESMO) Congress

 

 

LONDON AND PHILADELPHIA - July 30, 2025 - Avacta Therapeutics (AIM: AVCT, 'the
Company'), a life sciences company developing innovative, targeted oncology
drugs, today announces that the Company will present an updated data analysis
from the Phase 1a trial of FAP-Dox (AVA6000) at the 2025 European Society for
Medical Oncology (ESMO) Congress, in Berlin, Germany, taking place from
October 17-21, 2025. AVA6000 is a peptide drug conjugate consisting of
doxorubicin conjugated with a peptide moiety that is specifically cleaved by
FAP in the tumor microenvironment.

 

The poster presentation will be based on the most recent data analysis from
the Phase 1a trial of FAP-Dox (AVA6000) in patients with Fibroblast Activation
Protein (FAP)-positive solid tumors. Avacta completed the Phase 1a enrollment
dose escalation portion of the clinical trial in late 2024, with patient
enrollment ongoing in multiple dose expansion cohorts of a Phase 1b study.

 

Abstract details are listed below and available online on the ESMO website.

 

Avacta will hold an investor event shortly after the ESMO presentation.
Further details will be made available nearer the time.

 

Title: A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein
(FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide
drug conjugate in patients with FAP-positive solid tumors

Session Title: Developmental Therapeutics

Session Date and Time: 17 October, 19:40 - 20:00

Location: Berlin Auditorium - Hub 27

Abstract Presentation Number: 964P

Speaker: William D. Tap

 

 

-Ends-

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                           https://avacta.com/ (https://avacta.com/)

 Michael Vinegrad, Group Communications

 Director

 Peel Hunt (Nomad and Joint Broker)                         www.peelhunt.com (http://www.peelhunt.com)

 James Steel / Chris Golden

 Panmure Liberum (Joint Broker)                             www.panmureliberum.com (http://www.panmureliberum.com)

 Emma Earl / Will Goode / Mark Rogers

 Zeus (Joint Broker)                                        www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry

 Dominic King

 ICR Healthcare (Europe/UK media and investors)             avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com)

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

 Investor Contact                                           renee@thrustsc.com (mailto:renee@thrustsc.com)

 Renee Leck

 THRUST Strategic Communications

 Media Contact                                              Carly@carlyscadutoconsulting.com

                                                          (https://www.globenewswire.com/Tracker?data=YG-jwixFWaHByFwlhEr4NbVmhGc9YbrV0ozbiHY-33jDG-KDtaZDvqBLS4-5RgIi5zejtwvrLPO1U6xSYlV9BnK-dIegbuZft6wwj-ugstEWYrPDSrd9NwgKYBdm1l9Ty6VSa1gsRJqxeLaMfUN-easXzPVocBafm0xbzTKFahId-T7w4WgPYGYfKdFh6MGXNNniX0b0LrpQwjqHYj_mTmjerN3nRW6pwlbWejQ6wZCns0oke-U-WA7CB-Z2CD1ObedcWrqwKYgQwTY1NxAOLXtmHTL3VJ7HZ4Z3K9ZhB_2_vgbo4aKKTppE6l1bjU2w)
 Carly Scaduto

 Carly Scaduto Consulting

 

 

About Avacta - www.avacta.com
(https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.avacta.com%2F&data=05%7C02%7CChris.Coughlin%40avacta.com%7Ce5faa8dfbe3d49fc56f808dd35799958%7C64d2165ff9e04869bc73bfe4fc4fa9ab%7C0%7C0%7C638725518576703790%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=qWTC74zmTzjVQqwaFiKeiHUwMY5RUlsvb7C%2BkLRahGU%3D&reserved=0)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary payload delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent payloads in the tumor microenvironment
while sparing normal tissues. Our innovative pipeline consists of
pre|CISION(®) peptide drug conjugates (PDC) or Affimer(®) drug conjugates
(AffDC) that leverage the tumor-specific release mechanism, providing unique
benefits over traditional antibody drug conjugates.

 

About the pre|CISION(®) Platform

The pre|CISION(®) platform comprises an anticancer payload conjugated to a
proprietary peptide that is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumors compared
with healthy tissues. The pre|CISION(®) platform harnesses this tumor
specific protease to cleave pre|CISION(®) peptide drug conjugates and
pre|CISION(®) antibody/Affimer(®) drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and reducing
systemic exposure and toxicity, allowing dosing to be optimized to deliver the
best outcomes for patients.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCRMMATMTJJMLA